Hhlr Advisors LTD. boosted its position in shares of Danaher Co. (NYSE:DHR – Free Report) by 43.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 13,079 shares of the conglomerate’s stock after purchasing an additional 3,975 shares during the quarter. Danaher comprises about 0.1% of Hhlr Advisors LTD.’s holdings, making the stock its 27th biggest holding. Hhlr Advisors LTD.’s holdings in Danaher were worth $3,002,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Howard Capital Management Group LLC raised its position in Danaher by 4.1% in the 3rd quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate’s stock worth $342,000 after buying an additional 48 shares during the last quarter. Tudor Financial Inc. bought a new stake in shares of Danaher in the third quarter worth $414,000. Anchor Investment Management LLC increased its position in Danaher by 1.3% during the third quarter. Anchor Investment Management LLC now owns 6,039 shares of the conglomerate’s stock valued at $1,679,000 after acquiring an additional 78 shares during the last quarter. World Investment Advisors LLC boosted its position in Danaher by 5.3% in the third quarter. World Investment Advisors LLC now owns 12,948 shares of the conglomerate’s stock worth $3,600,000 after purchasing an additional 648 shares during the last quarter. Finally, Arvest Bank Trust Division bought a new stake in shares of Danaher during the 3rd quarter valued at about $254,000. 79.05% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.10% of the stock is owned by company insiders.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on Danaher
Danaher Price Performance
Shares of NYSE:DHR opened at $196.01 on Tuesday. Danaher Co. has a 12 month low of $171.00 and a 12 month high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The company has a 50 day moving average of $200.69 and a 200 day moving average of $223.46. The stock has a market cap of $140.28 billion, a P/E ratio of 37.12, a P/E/G ratio of 2.66 and a beta of 0.86.
Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.26. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.58 billion. Danaher had a net margin of 16.33% and a return on equity of 10.82%. As a group, sell-side analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.
Danaher Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, April 25th. Investors of record on Friday, March 28th were issued a dividend of $0.32 per share. This is an increase from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 annualized dividend and a dividend yield of 0.65%. The ex-dividend date of this dividend was Friday, March 28th. Danaher’s dividend payout ratio is currently 24.85%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Recommended Stories
- Five stocks we like better than Danaher
- Conference Calls and Individual Investors
- 5 Mid-Cap Stocks Insiders Are Buying This Year
- Should You Invest in Penny Stocks?
- Should You Ditch Index Funds? Why High-Yield ETFs Might Be Better
- What is a Secondary Public Offering? What Investors Need to Know
- Southwest Airlines CEO Calls Recession, Why Option Traders Jumped
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.